Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics

Observations from real-world data

Christopher Kim, Sumita Bhatta, Lori Cyprien, Rafael Fonseca, Rohini K. Hernandez

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Skeletal-related events (SREs) are common bone complications in multiple myeloma (MM). However, there are few real-world reports of their incidence. In this study, a database of oncology electronic health records was linked to administrative claims data. Patients identified were aged ≥18 years and newly diagnosed with MM, had ≥1 clinic visit within 1 month of diagnosis, and ≥1 year of follow-up after diagnosis. The study period was January 1, 2011 to December 31, 2016. 343 patients were included, 35% of whom had a baseline history of any SRE. During a median follow-up of 25.7 months, 34% of patients experienced SREs after diagnosis. Median time to SRE was 167 days. Among patients experiencing an SRE, 68% had an SRE within the first year. The incidence rate of SREs at 1 year following MM diagnosis for patients with baseline history was 103/100 person-years (PY) versus 16/100PY for patients without baseline history. SRE incidence rates within 3 months of initiating a line of therapy increased with subsequent lines (line 1: 81/100PY, line 2: 118/100PY, line 3: 150/100PY). Risk of SREs was similar across different anti-MM regimens, including proteasome inhibitor-based regimens. These results highlight the importance of continued surveillance and management of MM-associated bone disease.

Original languageEnglish (US)
Article number100215
JournalJournal of Bone Oncology
Volume14
DOIs
StatePublished - Feb 1 2019

Fingerprint

Multiple Myeloma
Incidence
History
Proteasome Inhibitors
Electronic Health Records
Bone Diseases
Ambulatory Care
Databases
Bone and Bones

Keywords

  • Bone disease
  • Multiple myeloma
  • Proteasome inhibitor
  • Skeletal-related event

ASJC Scopus subject areas

  • Oncology

Cite this

Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics : Observations from real-world data. / Kim, Christopher; Bhatta, Sumita; Cyprien, Lori; Fonseca, Rafael; Hernandez, Rohini K.

In: Journal of Bone Oncology, Vol. 14, 100215, 01.02.2019.

Research output: Contribution to journalArticle

@article{11d0d09939894647911958a1853aa354,
title = "Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics: Observations from real-world data",
abstract = "Skeletal-related events (SREs) are common bone complications in multiple myeloma (MM). However, there are few real-world reports of their incidence. In this study, a database of oncology electronic health records was linked to administrative claims data. Patients identified were aged ≥18 years and newly diagnosed with MM, had ≥1 clinic visit within 1 month of diagnosis, and ≥1 year of follow-up after diagnosis. The study period was January 1, 2011 to December 31, 2016. 343 patients were included, 35{\%} of whom had a baseline history of any SRE. During a median follow-up of 25.7 months, 34{\%} of patients experienced SREs after diagnosis. Median time to SRE was 167 days. Among patients experiencing an SRE, 68{\%} had an SRE within the first year. The incidence rate of SREs at 1 year following MM diagnosis for patients with baseline history was 103/100 person-years (PY) versus 16/100PY for patients without baseline history. SRE incidence rates within 3 months of initiating a line of therapy increased with subsequent lines (line 1: 81/100PY, line 2: 118/100PY, line 3: 150/100PY). Risk of SREs was similar across different anti-MM regimens, including proteasome inhibitor-based regimens. These results highlight the importance of continued surveillance and management of MM-associated bone disease.",
keywords = "Bone disease, Multiple myeloma, Proteasome inhibitor, Skeletal-related event",
author = "Christopher Kim and Sumita Bhatta and Lori Cyprien and Rafael Fonseca and Hernandez, {Rohini K.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.jbo.2018.100215",
language = "English (US)",
volume = "14",
journal = "Journal of Bone Oncology",
issn = "2212-1374",
publisher = "Elsevier GmbH",

}

TY - JOUR

T1 - Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics

T2 - Observations from real-world data

AU - Kim, Christopher

AU - Bhatta, Sumita

AU - Cyprien, Lori

AU - Fonseca, Rafael

AU - Hernandez, Rohini K.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Skeletal-related events (SREs) are common bone complications in multiple myeloma (MM). However, there are few real-world reports of their incidence. In this study, a database of oncology electronic health records was linked to administrative claims data. Patients identified were aged ≥18 years and newly diagnosed with MM, had ≥1 clinic visit within 1 month of diagnosis, and ≥1 year of follow-up after diagnosis. The study period was January 1, 2011 to December 31, 2016. 343 patients were included, 35% of whom had a baseline history of any SRE. During a median follow-up of 25.7 months, 34% of patients experienced SREs after diagnosis. Median time to SRE was 167 days. Among patients experiencing an SRE, 68% had an SRE within the first year. The incidence rate of SREs at 1 year following MM diagnosis for patients with baseline history was 103/100 person-years (PY) versus 16/100PY for patients without baseline history. SRE incidence rates within 3 months of initiating a line of therapy increased with subsequent lines (line 1: 81/100PY, line 2: 118/100PY, line 3: 150/100PY). Risk of SREs was similar across different anti-MM regimens, including proteasome inhibitor-based regimens. These results highlight the importance of continued surveillance and management of MM-associated bone disease.

AB - Skeletal-related events (SREs) are common bone complications in multiple myeloma (MM). However, there are few real-world reports of their incidence. In this study, a database of oncology electronic health records was linked to administrative claims data. Patients identified were aged ≥18 years and newly diagnosed with MM, had ≥1 clinic visit within 1 month of diagnosis, and ≥1 year of follow-up after diagnosis. The study period was January 1, 2011 to December 31, 2016. 343 patients were included, 35% of whom had a baseline history of any SRE. During a median follow-up of 25.7 months, 34% of patients experienced SREs after diagnosis. Median time to SRE was 167 days. Among patients experiencing an SRE, 68% had an SRE within the first year. The incidence rate of SREs at 1 year following MM diagnosis for patients with baseline history was 103/100 person-years (PY) versus 16/100PY for patients without baseline history. SRE incidence rates within 3 months of initiating a line of therapy increased with subsequent lines (line 1: 81/100PY, line 2: 118/100PY, line 3: 150/100PY). Risk of SREs was similar across different anti-MM regimens, including proteasome inhibitor-based regimens. These results highlight the importance of continued surveillance and management of MM-associated bone disease.

KW - Bone disease

KW - Multiple myeloma

KW - Proteasome inhibitor

KW - Skeletal-related event

UR - http://www.scopus.com/inward/record.url?scp=85059700411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059700411&partnerID=8YFLogxK

U2 - 10.1016/j.jbo.2018.100215

DO - 10.1016/j.jbo.2018.100215

M3 - Article

VL - 14

JO - Journal of Bone Oncology

JF - Journal of Bone Oncology

SN - 2212-1374

M1 - 100215

ER -